By: Yekta Dowlati, PhD

Pain is not merely a symptom; it is the consequence of disrupted immune resolution, tissue stress, metabolic dysfunction, and maladaptive neuroplasticity. The historical emphasis on symptom suppression through analgesics and anti-inflammatory drugs has overlooked the body’s own endogenous mechanisms for controlling inflammation and restoring homeostasis. As a result, conventional therapies often provide only temporary relief, while doing little to address the biological underpinnings of chronic pain. Emerging research in resolution biology, enzymatic signaling, and phytochemical immunomodulation offers a more targeted and sustainable approach to pain management.^1-4 This review highlights three non-pharmacologic, mechanistically distinct strategies:

1. Supporting endogenous resolution pathways through specialized pro-resolving mediators (SPMs)
2. Attenuating acute enzymatic drivers of inflammation via dual cyclooxygenase (COX)/lipoxygenase (LOX) inhibition
3. Employing botanicals that modulate multiple inflammatory and neuroimmune targets implicated in chronic pain

Activating Endogenous Resolution Pathways

Inflammation is an essential and tightly regulated biological process. However, its resolution is not passive—it is an active, receptor-mediated sequence involving a class of lipid-derived mediators known as SPMs. These include resolvins (RvD1, RvE1), protectins, maresins, and lipoxins, which are biosynthesized from the omega-3 fatty acids EPA and DHA during the late inflammatory phase mainly via 15-LOX and 5-LOX enzymatic pathways.²

SPMs act through G-protein coupled receptors (GPCRs) such as ChemR23 (RvE1), GPR32 (RvD1), and ALX/FPR2, which are expressed on monocytes, macrophages, dendritic cells, glial cells, and nociceptive neurons.² Their binding initiates transcriptional programs that suppress neutrophil infiltration, enhance macrophage-mediated efferocytosis of apoptotic cells, inhibit pro-inflammatory cytokine expression, and restore vascular and epithelial integrity.² In the context of nociception, SPMs modulate transient receptor potential vanilloid 1 (TRPV1) ion channels, attenuate spinal microglial activation, and reduce NMDA receptor excitotoxicity—mechanisms implicated in chronic pain, central sensitization, and hyperalgesia.³

In a 4-week, open-label trial of 44 adults with ≥3 months of moderate-to-severe chronic pain, oral supplementation with a marine lipid concentrate standardized to 17-HDHA and 18-HEPE significantly improved PROMIS-43 quality-of-life domains, including fatigue (−2.61; p<0.02), sleep disturbance (−3.35; p<0.001), physical function (+3.40; p<0.001), and social function (+3.70; p<0.001), with borderline gains on the ACPA QOL scale (p=0.051).⁵ Pain intensity decreased (−1.64; p<0.0001) alongside reductions in worst (−1.05; p<0.002) and average (−1.45; p<0.0001) pain, pain interference (−3.99; p<0.0001), depression (−2.16; p<0.018; PROMIS-43), and anxiety (−3.71; p<0.0001).⁵

The bioactivity of SPMs depends critically on the availability of precursors (e.g., 17-HDHA, 18-HEPE), enzymatic conversion efficiency, and tissue-specific receptor expression.² Moreover, SPMs are structurally labile, oxidatively sensitive, and metabolized rapidly. Delivery systems that enrich SPM precursors in their bioactive stereoisomeric forms, protect against oxidative degradation, and promote mucosal uptake are essential for achieving clinical efficacy. Lipid matrix-based delivery may enhance lymphatic transport and tissue integration, bypassing hepatic metabolism and preserving molecular integrity.²

Acute Pain and Enzymatic Inhibition: Dual Targeting of COX/LOX

Acute inflammatory pain arises from the immediate activation of nociceptors and inflammatory mediators in response to injury or tissue insult. Botanicals such as Curcuma longa (curcumin) and Boswellia serrata (standardized to boswellic acids) offer mechanistically distinct and complementary pathways for pain modulation, targeting both COX and LOX signaling cascades.^6-14

Curcumin exerts anti-inflammatory effects primarily by suppressing NF-κB activation and reducing downstream expression of COX-2, inducible nitric oxide synthase (iNOS), and proinflammatory cytokines including TNF-α and IL-1β. It also interacts with TRP channels involved in nociceptive transduction, thereby dampening peripheral sensitization and pain transmission.^6-9

Boswellic acids, particularly acetyl-11-keto-β-boswellic acid (AKBA), are potent inhibitors of 5-LOX, thereby blocking leukotriene synthesis. AKBA has also been shown to suppress microsomal prostaglandin E2 synthase-1 (mPGES-1), further reducing prostanoid-mediated inflammation while sparing constitutive COX-1 activity, which may preserve gastric mucosal protection.^10-13 Boswellia also suppresses NF-κB, reducing pro-inflammatory cytokines and nociceptor sensitization. By inhibiting matrix metalloproteinases (MMPs), it also prevents tissue breakdown, easing inflammatory pain.¹³

Because both curcumin and boswellic acids are lipophilic and poorly soluble in water, innovative delivery technologies are essential to achieve rapid and effective absorption. Oil-based dispersion systems, such as micellar matrices or phospholipid-rich carriers, have been shown to enhance solubilization in the gastrointestinal tract, promote lymphatic uptake, and bypass first-pass hepatic metabolism. These strategies significantly improve bioavailability and onset of clinical effect, offering a compelling pharmacokinetic advantage over conventional extracts.^15-17

In a randomized study involving 88 individuals with acute musculoskeletal pain, 1000 mg/d of Rhuleave-k (a combination of curcumin, boswellia, and black sesame oil) provided a 53.1% reduction in pain at 6 hours, statistically comparable to 1,000 mg acetaminophen (55.4%)—with improvements in physical function and patient satisfaction over 7 days.¹⁸ A separate double-blind, placebo-controlled trial in 232 adults with exercise-induced pain demonstrated a significant reduction in pain scores starting within 60 minutes, with a >70% reduction within 3 hours (p<0.001).¹⁹

Taken together, the use of bioavailable curcumin and boswellia extracts represents a scientifically validated strategy for managing acute pain with a rapid onset and reduced safety concerns relative to conventional analgesics.

Timing and Delivery: Rapid vs. Steady Therapeutic Onset

Many bioactive compounds—especially those with overlapping targets—exert their efficacy not only through what they do, but also how fast and how consistently they reach their targets. Two formulas with identical ingredients can have dramatically different clinical utility based on the pharmacokinetics of absorption and circulation.

Advanced dispersion technologies allow certain anti-inflammatory actives to be rapidly absorbed, producing early plasma-level spikes. This is particularly advantageous for fast-acting relief in acute pain settings.^15-17 In contrast, traditional matrix delivery formats offer slower, more sustained release over time, better suited for long-term management of chronic or relapsing pain.²⁰

Clinically, this distinction informs the use of fast-absorbing delivery systems for immediate needs (e.g., post-exercise, acute strain) versus matrix-based systems for daily use in chronic inflammatory conditions or recurrent joint discomfort. While the molecular targets—such as NF-κB, COX-2, and 5-LOX—remain the same, the onset of action and duration of efficacy are governed by the delivery platform.

Multi-Botanical Support for Chronic and Systemic Inflammation

For pain states rooted in chronic inflammation—whether musculoskeletal, menstrual, neuroimmune, or exercise-induced—polyphenolic and triterpenoid-rich botanicals may offer synergistic modulation of immune and neuronal pathways.^21-23

Botanical compounds like gingerol, quercetin, boswellic acids, and curcuminoids suppress upstream transcriptional regulators such as NF-κB and MAPKs. They also inhibit non-enzymatic drivers like toll-like receptor signaling and glial activation, mechanisms implicated in central sensitization and neuroinflammation.^6-14

Ginger (Zingiber officinale), for instance, not only inhibits prostaglandins and leukotrienes via partial 5-LOX blockade, but also reduces substance P release and modulates TRPV1 ion channels. Its primary actives (gingerols, shogaols) have been shown to suppress IκB phosphorylation, thereby preventing NF-κB nuclear translocation and reducing expression of TNF-α and IL-6.^24-26

Fenugreek (Trigonella foenum-graecum) introduces an additional layer of bioactivity. Its galactomannan fibers may enhance dispersion and mucosal uptake of co-administered lipophilic actives. Simultaneously, fenugreek’s saponins and flavonoids exert antioxidant and anti-inflammatory effects through nitric oxide modulation and NF-κB suppression.²⁷

The application of this broader strategy is particularly relevant for individuals experiencing recurrent pain, exercise-associated inflammation, degenerative joint changes, or systemic pain states involving fatigue, mood dysregulation, or central sensitization. In such populations, the therapeutic goal extends beyond immediate analgesia to include resolution of chronic immune activation, neuroprotection, and restoration of cellular homeostasis.

Conclusion: Precision Strategies for Pain Through Resolution and Modulation

The evolution of pain management lies in shifting from symptomatic suppression to upstream resolution and immune recalibration. This requires a mechanistic understanding of:

• Resolution biology (SPMs, lipid mediators)
• Enzymatic inhibition (COX/LOX blockade)
• Neuroimmune modulation (botanical signaling)
• Pharmacokinetics (delivery speed, duration, absorption window)

Together, these factors determine clinical outcomes. A shared ingredient profile may offer flexible options across both acute and chronic indications, but differences in delivery science enable tailored therapeutic approaches.

For healthcare providers, this means aligning patient goals (fast relief vs. sustained modulation) with an appropriate strategy—whether rapid-absorption formats for immediate use or matrix-based systems for long-term inflammation support.

References

1. Peh HY et al. Pharmacol Ther. 2025;265:108753.
2. Serhan CN et al. Curr top Med Chem. 2011;11(6):629-647.
3. Serhan CN. Nature. 2014;510(7503):92-101.
4. Serhan CN et al. Semin Immunol. 2015;27(3):200-215.
5. Callan N et al. J Transl Med. 2020;18:401.
6. Peng Y et al. Drug Des Devel Ther. 2021;15:4503-4525.
7. Rao CV. Adv Exp Med Biol. 2007;595:213-226.
8. Zhi L et al. Neurogastroenterol Motil. 2013;25(6):e429-e440.
9. Wal P et al. Open Med J. 2019;6:64-76.
10. Martel-Pelletier J et al. Ann Rheum Dis. 2003;62(6):501-509.
11. Raja AF et al. BMC Res Notes. 2011;4:406.
12. Bishnoi M et al. Indian J Exp Biol. 2006;44(2):128-132:16480179.
13. Dubey V et al. Explore (NY). 2024;20(5):102983.
14. Gupta M et al. S Afr J Bot. 2021;143:205-225.
15. Schiborr C et al. Mol Nutr Food Res. 2014;58(3):516-527.
16. Meins J et al. NFS Journal. 2018;11:12-16.
17. Bali S et al. J Ayurveda Integr Med. 2021;13(2):100526.
18. Rudrappa GH et al. Medicine. 2020;99(28):e20373.
19. Murthy M et al. Sch J App Med Sci. 2022;3:311-326.
20. Pundir S et al. Int J Drug Res Tech. 2013;3(1):12-20.
21. Yahfoufi N et al. Nutrients. 2018;10(11):1618.
22. Jantan I et al. J Nutr Biochem. 2021;93:108634.
23. Renda G et al. Phytochem Rev. 2021;21(2):537-563.
24. Mao QQ et al. Foods. 2019;8(6):185.
25. Yucel C et al. Front Pharmacol. 2022;13:902551.
26. Andrei C et al. Nutraceuticals. 2022;2(4):384-403.
27. Abhilash MB et al. J Funct Foods. 2021;79(4):104405.

Yekta Dowlati, PhD, serves as the Medical Education Manager at Metagenics. Dr. Dowlati earned her PhD in Medical Sciences from the University of Toronto, along with her MSc in Pharmacology. Her academic credentials also include a BSc in nutrition. She furthered her expertise with a postdoctoral fellowship in Neuropsychopharmacology at the Centre for Addiction and Mental Health in Toronto. Dr. Dowlati’s research portfolio includes multiple clinical trials, and she has contributed to the scientific community through her authorship and co-authorship of articles in prestigious journals, alongside presenting her work at numerous national and international conferences. Before her tenure at Metagenics, she excelled as a senior medical writer and led medical writing teams, demonstrating her passion for learning and education to improve public health. Beyond her professional commitments, Dr. Dowlati cherishes family time, indulging in travel, fitness, and cooking, which speaks to her balanced approach to life.